At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed prostate cancer
- ✓Metastatic disease documented
- ✓On androgen-deprivation therapy for less than 120 days at enrollment
- ✓ECOG performance status 0–2 (PS 2 only if decline is due to metastatic prostate cancer)
- ✕PSA progression since start of androgen-deprivation therapy (rise from nadir meeting progression criteria)
- ✕Prior malignancy within 5 years except nonmelanoma skin cancer
- ✕Peripheral neuropathy greater than grade 1
- ✕History of severe hypersensitivity to docetaxel or polysorbate 80–formulated drugs
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating androgen-deprivation therapy and docetaxel for Metastatic Hormone-sensitive Prostate Cancer. Completed, enrolled 790 participants across 343 sites.
Detailed Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Study Details
Timeline
Interventions
LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
Given IV